Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06600659 · ClinicalTrials.gov registry record

A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase

A clinical trial of Hematopoietic and Lymphatic System Neoplasm and Acute Lymphobkastic Leukemia, sponsored by Mayo Clinic.

Recruiting
Registry status
10
Enrollment target
1
Study location

NCT06600659 is a study of Hematopoietic and Lymphatic System Neoplasm and Acute Lymphobkastic Leukemia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 10 participants, below the 483-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06600659, a study of Hematopoietic and Lymphatic System Neoplasm and Acute Lymphobkastic Leukemia, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
10 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

Interventions

  • OTHER Non-Interventional Study

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2023-11-02
Est. Completion 2026-12-01

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06600659

The ClinicalTrials.gov registry entry for NCT06600659 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 62 other Hematopoietic and Lymphatic System Neoplasm trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Hematopoietic and Lymphatic System Neoplasm appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT06600659 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06600659 about?

NCT06600659 is a clinical study titled "A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase". This study evaluates the incidence of symptomatic hyperammonemia (high ammonia levels) in patients being treated with recombinant Erwinia asparaginase.

What is the current status of trial NCT06600659?

This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2023-11-02. Estimated completion is 2026-12-01.

What conditions does trial NCT06600659 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphatic System Neoplasm, Acute Lymphobkastic Leukemia.

What interventions are being tested in trial NCT06600659?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT06600659?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06600659 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematopoietic and Lymphatic System Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.